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AbstrACt
Objective Severe infections are a major cause of 
morbidity and mortality in patients with systemic lupus 
erythematosus (SLE). Our primary objective was to use 
data from a large Spanish cohort to develop a risk score 
for severe infection in SLE, the SLE Severe Infection Score 
(SLESIS) and to validate SLESIS in a separate cohort of 
699 British patients.
Design and setting Retrospective longitudinal study in a 
specialist tertiary care clinic in London, UK.
Participants Patients fulfilling international classification 
criteria for SLE (n=209). This included 98 patients who had 
suffered severe infections (defined as infection leading to 
hospitalisation and/or death) and 111 randomly selected 
patients who had never suffered severe infections.
Outcomes We retrospectively calculated SLESIS at 
diagnosis for all 209 patients. For the infection cases we 
also calculated SLESIS just prior to infection and compared 
it to SLESIS in 98 controls matched for disease duration. 
We carried out receiver operator characteristic (ROC) 
analysis to quantify predictive value of SLESIS for severe 
infection.
results Median SLESIS (IQR) at diagnosis was higher in 
the infection group than in the control group (4.27 (3.18) 
vs 2.55 (3.79), p=0.0008). Median SLESIS prior to infection 
was higher than at diagnosis (6.64 vs 4.27, p<0.001). In 
ROC analysis, predictive value of SLESIS just before the 
infection (area under the curve (AUC)=0.79) was higher 
than that of SLESIS at diagnosis (AUC=0.63).
Conclusions We validated the association of SLESIS with 
severe infection in an independent cohort. Calculation of 
SLESIS at each clinic visit may help in management of 
infection risk in patients with SLE. Prospective studies are 
needed to confirm these findings.
IntrODuCtIOn
Systemic lupus erythematosus (SLE) is a 
systemic autoimmune disease that mainly pres-
ents in women aged between 30 years and 50 
years. Infection is a major cause of morbidity 
and mortality in patients with SLE, being 
responsible for 11%–45% of hospitalisations 
as well as 20%–55% of deaths, according to 
different studies.1–6 
There are immunological and genetic 
disorders that predispose to the development 
of infections in patients with SLE.7 8 Respira-
tory tract infections are the most common 
infections in these patients, and bacteraemia 
the leading cause of mortality. Regarding 
the aetiology, pathogenic bacteria are most 
frequently involved in the infection, followed 
by viruses and fungi.9 10
There are several well-established risk 
factors for infection such as age at diagnosis, 
male sex, ethnicity and use of corticosteroids, 
among others; however, the independent 
contribution of each factor is not well under-
stood.11–14 On the other hand, severe infec-
tions have been associated with decreased 
survival of patients with SLE, acting as an 
strengths and limitations of this study
 ► We developed an algorithm (Systemic Lupus 
Erythematosus Severe Infection Score (SLESIS)) 
designed to predict the risk of severe infections in 
patients with systemic lupus erythematosus  (SLE) 
that could be a useful tool in clinical practice.
 ► SLESIS was developed using data from a Spanish 
lupus registry (Spanish Society of Rheumatology 
Lupus Registry (RELESSER)) that includes almost 
4000 patients with SLE.
 ► We applied the algorithm in a British cohort of 699 
patients with SLE in order to validate it.
 ► The algorithm consists of seven variables that are 
all obtainable from information obtained in routine 
clinical practice.
 ► We acknowledge several limitations: the retrospec-
tive design of the study, the different ethnicity in the 
Spanish and British populations and the Katz Index 
as an item of the score.
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independent risk factor for mortality at 10 years after 
diagnosis.2–4 14
This information about the risk factors associated with 
infection in SLE has not yet been combined into tools 
to estimate the risk of severe infection in individual 
patients over time. The development of an algorithm for 
predicting the risk of severe infection could be very useful 
to monitor risk factors more closely in a weighted way. It 
could allow us to implement prophylactic measures such 
as vaccination in the highest-risk patients and to consider 
early intervention such as antibiotic therapy in this group 
of patients with the ultimate goal of reducing morbidity 
and improving survival.15–17 Similar scores to predict risk 
of severe infection have been developed and validated in 
patients with rheumatoid arthritis (RA) with encouraging 
results.18
In a recent original study from the Spanish Society of 
Rheumatology Lupus Registry (RELESSER), the authors 
studied 3658 patients with SLE, of whom 705 (19.3%) 
had suffered one or more severe infections. A multivari-
able Cox regression model for repeated events (Ander-
sen-Gill) was used to define the impact of a range of 
demographic and clinical variables on the risk of devel-
oping severe infection, expressed as HR of developing 
severe infection for patients with each associated factor, 
compared with those without that factor.17 Seven factors 
had an HR more than 1.
In the study reported in the current paper these seven 
factors were used to generate a score—the Systemic 
Lupus Erythematosus Severe Infection Score (SLESIS), 
designed to predict the risk that a patient with lupus will 
develop a severe infection.
The overarching primary objective of the current study 
was to validate SLESIS in an independent population of 
patients with SLE from London, UK.
In the validation cohort, we aimed to answer three 
questions.
1. Does SLESIS at the time of diagnosis predict future se-
vere infection?
2. In patients who suffer a severe infection, does SLESIS 
change between diagnosis and the time of infection?
3. Does SLESIS just prior to an infection predict future 
severe infection?
If (2) and (3) are true, it could support assessing SLESIS 
at every appointment rather than only at diagnosis.
PAtIents AnD methODs
Development and definition of sLesIs
SLESIS was developed using variables related to infection 
from the RELESSER cohort of 3658 patients with SLE 
who meet ≥4  critera of the American College of Rheu-
matology (ACR) classification criteria for SLE. The vari-
ables, definitions and methodological characteristics of 
the RELESSER registry have previously been described in 
detail.19 20
Table 1 shows the seven factors that were found to 
be associated with increased risk of developing severe 
infection (defined as infection leading to hospitalisa-
tion and/or death) in the RELESSER paper17 together 
with HR for severe infection associated with each factor. 
There are four factors that are graded present or absent; 
age at diagnosis >46 years (HR = 1.12); Latin American 
ethnicity (HR=2.4); dose of corticosteroid ≥10 mg/day 
(HR = 1.33); and male sex (HR = 1.49). For each of these 
factors, the contribution to SLESIS is either 0 (if absent) 
or 1 × HR (if present).
One factor (Katz Index21 of disease severity) is a contin-
uous variable. The contribution of this factor is its abso-
lute value × 1.06 (its HR).
The other factors are previous hospitalisations for SLE 
(HR = 2.73) and previous severe infection (HR = 2.40). 
For these factors the contribution to SLESIS is the 
number of events × HR.
Thus SLESIS for a male Latin American patient, diag-
nosed at age 22 years, taking 12 mg prednisolone per day 
with a Katz Index of 2, two previous hospitalisations for 
SLE and no previous severe infections would be calcu-
lated as follows.
(0 × 1.12) + (1 × 2.4) + (1 × 1.33) + (1 × 1.49) + (2 × 1.06) 
+ (2 × 2.73) + (0 × 2.40) = 11.31.
Conversely SLESIS for a female Chinese patient, diag-
nosed at age 50 years, taking 5 mg prednisolone per day 
with a Katz Index of 2, no previous hospitalisations for 
SLE and three previous severe infections would be calcu-
lated as follows.
Table 1 Variables incorporated into SLESIS
Variable β coefficient HR for severe infection 95% CI
Age at diagnosis (>46 years) 0.1163 1.12 1.07 to 1.18
Latin American ethnicity 0.427 2.40 2.29 to 2.5
Current dose of corticosteroids ≥10 mg/day 0.2878 1.33 1.15 to 1.55
Sex (male) 0.3692 1.49 1.22 to 1.81
Previous hospitalisation for SLE 1.0049 2.73 2.22 to 3.35
Katz Index21 0.062 1.06 1.03 to 1.1
Each previous severe infection 0.8739 2.40 2.29 to 2.50
These HR values were derived from the retrospective analysis of 3658 Spanish patients described in ref [17].
SLE, systemic lupus  erythematosus; SLESIS, Systemic Lupus Erythematosus Severe Infection Score. 
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(1 × 1.12) + (0 × 2.4) + (0 × 1.33) + (0 × 1.49) + (2 × 1.06) 
+ (0 × 2.73) + (3 × 2.40) = 10.44.
Validation cohort
Validation was carried out in the lupus clinic at University 
College London Hospital (UCLH). All patients fulfilled 
the 1997 revised criteria of ACR for the classification of 
SLE.22 The clinic has been running continuously since 
1979 and has records from 699 patients. Medical records 
of all the patients were reviewed to identify those who had 
suffered severe infections. Severe infection was defined 
as that leading to hospitalisation and/or death. Isolation 
of the causative agent was not required in every case, 
with final classification as an infection being made using 
standard clinical criteria as in the previous RELESSER 
Study.17 Only infections recorded during the follow-up 
period (ie, after the diagnosis of lupus) were included 
as outcomes.
We used a nested case-control design. We identified 
98 patients who had suffered at least one severe infec-
tion and compared their medical records with those of 
111 randomly selected patients with SLE who had never 
suffered from severe infections. By retrospective analysis 
of medical records, we obtained comprehensive informa-
tion about demographic, clinical, serological and treat-
ment factors in these two groups.
We calculated SLESIS for each of the 209 patients at the 
time of diagnosis. For each of the 98 patients with infec-
tion we also calculated SLESIS for the clinical assessment 
carried out at the last consultation prior to the infection. 
For comparison, we calculated SLESIS in 98 controls 
matched for disease duration, as follows. For each infec-
tion case we selected one control case from the 111 who 
had never suffered severe infections. For the control 
we calculated SLESIS at the time point after diagnosis 
corresponding to the duration after diagnosis when the 
matched case suffered severe infection.
statistical analysis
Demographic and clinical characteristics were compared 
between patients who developed severe infection and 
patients who did not, using a Pearson χ2 for categorical 
variables or a Student’s t-test for normally distributed 
continuous variables (data expressed as mean±SD). 
For non-normally distributed variables, either a Mann-
Whitney U test or a logarithmic transformation was 
performed, and data are expressed as median and IQR. 
Multivariable logistic regression analysis was performed 
to establish which factors were independently associated 
with severe infection.
We compared SLESIS scores between case and control 
groups using the Mann-Whitney U test. Receiver oper-
ator characteristics (ROC) analysis was used to define the 
area under the curve (AUC) for SLESIS at diagnosis and 
SLESIS just prior to infection. We also identified several 
possible cut-off scores for SLESIS with different combina-
tions of specificity and sensitivity for severe infection.
The STATA for Windows statistical software package 
(V.13.1) was used for all statistical analysis. Significance 
was defined as p<0.05.
Patients and/or public involvement
Patients and/or public were not involved in this study.
resuLts
Table 2 shows a comparison of 98 patients (14% of 
the total cohort of 699 patients) who developed severe 
infection and a control group of 111 patients who never 
suffered from severe infection. These two groups did not 
differ in age, sex or ethnicity.
Patients who developed severe infections after diagnosis 
of SLE were more likely to have suffered previous severe 
infections before diagnosis of SLE (Pearson χ2=11.69, 
p=0.001) or to have been hospitalised for SLE (Pearson 
χ2=11.89, p=0.001) compared with those patients who 
never had severe infections. In terms of SLE manifes-
tations, skin and renal disease were more common in 
the infection group (Pearson χ2=6.25, p=0.012; Pearson 
χ2=9.5, p=0.004) whereas joint involvement was more 
frequent in the non-infection group (Pearson χ2=11.21, 
p=0.001).
Patients in the infection group were more likely to 
have been treated with high doses of corticosteroids or 
an immunosuppressant (IS). Whereas 55% of the infec-
tion group had ever been treated with corticosteroids at 
a dose >10 mg per day, this only happened in 22% of the 
non-infected group (Pearson χ2=10.54, p=0.009). Signifi-
cantly increased risk of infection was found for azathio-
prine (Pearson χ2=5.89 p=0.015) and cyclophosphamide 
(Pearson χ2=8.26, p=0.004) but not for mycophenolate or 
rituximab. Hydroxychloroquine (HCQ) had been taken 
by 77% of the non-infection group compared with 67% 
of the infection group with no significant difference 
between groups.
Regarding laboratory data, only neutropenia, which was 
twice as common in the infection group (34% vs 17%), 
was significantly different between both groups (Pearson 
χ2=7.63, p=0.006).
After multivariable analysis adjusted for age, only 
previous infection (β coefficient: 2.20, 95% CI 0.77 to 3.62; 
p=0.003), previous hospitalisations for SLE (β coefficient: 
1.12, 95% CI 0.19 to 2.07; p=0.021) and treatment with 
corticosteroids ≥10 mg/day, (β coefficient: 3.39, 95% CI 
2.33 to 4.44; p<0.001) remained statistically significant.
type of infection
The most common type of severe infection was respiratory 
tract infection (n=29; 29.6% of all infections), followed 
by urinary tract infection (n=22, 22.4%) and gastroin-
testinal infection (n=22, 22.4%). Less frequent were soft 
tissue infection (n=11, 11.2%) and nervous system infec-
tions (n=4, 4.1%). Twelve (12.4%) of the patients devel-
oped documented bacteraemia on blood culture and 15 
(15.3%) had multiple organ involvement.
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mortality
About a quarter (26.5%) of the patients died during 
their admission for severe infection, though this does 
not imply that death was always due to infection as many 
patients had comorbidities or active lupus as well. Having 
recorded this high proportion of deaths, we analysed the 
differences between the group of 26 patients who died 
during their admission for infection and the 72 patients 
who survived. These results are summarised in table 3.
Patients who did not die had more previous hospi-
talisations due to SLE, compared with those who died 
(Pearson χ2=33.71, p=<0.001). In contrast, those who 
died were more likely to have suffered from severe infec-
tions prior to the diagnosis of SLE (Pearson χ2=8.66, 
p=0.003).
There were no statistically significant differences 
among the clinical manifestations of SLE between these 
two groups.
Table 2 Descriptive data: patients with systemic lupus erythematosus (SLE) with infection versus without infection
Study (infection) group 
(n=98)
Control (non-infection) 
group (n=111) P values
Gender, n (%) 90 (92) 103 (93)
Female (male) 8 (8) 8 (7) ns
Median age at diagnosis of SLE (IQR), years 30.5 (27) 31 (18) ns
Median age at time of infection (IQR), years 43 (25) Not applicable
Ethnicity, n (%)
  Caucasian 48 (49) 72 (65) ns
  Hispanics 3 (3) 2 (2)
  Afro-Caribbean 28 (29) 20 (18)
  Asian 7 (7) 6 (5)
  Other 12 (12) 12 (11)
  Median length of follow-up (IQR), years 9.5 (14) 14 (9) ns
  Previous infection before SLE diagnosis,n (%) 16 (16) 3 (2) 0.001
  Previous hospitalisations due to SLE n (%) 55 (56) 36 (32) 0.001
SLE main features (cumulative) n, (%)
  Skin disease 76 (78) 67 (60) 0.012
  Joint disease 72 (74) 101 (91) 0.001
  Renal disease 42 (43) 24 (22) 0.004
  Neuropsychiatric disease 13 (13) 12 (11) ns
  Serositis 19 (19) 33 (30) ns
Previous drug treatment n (%)
  Corticosteroids 89 (91) 43 (39) <0.001
  Corticosteroids (≥10 mg per day at any time) 54 (55) 25 (23) 0.009
  No hydroxychloroquine 32 (33) 25 (23) ns
  Azathioprine 47 (48) 35 (32) 0.015
  Mycophenolate 36 (35) 28 (25) ns
  Cyclophosphamide 28 (29) 13 (13) 0.004
  Rituximab 26 (27) 25 (23) ns
Laboratory data, n(%) at any time
  Neutropenia 33 (34) 19 (17) 0.006
  Lymphopenia 76 (78) 73(66) ns
  Anti-dsDNA + 67 (68) 66 (60) ns
  Low C3 57 (58) 50 (45) ns
Outcomes
  Deaths 26 (27) 2 (2)
  Patients with >1 infection 18 (18) 0 0.03
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Regarding treatment, there were statistically significant 
differences for steroids at any time (Pearson χ2=8.19, 
p=0.004) and rituximab (Pearson χ2=9.34, p=0.002). 
However, for both these variables, patients who survived 
were more likely to have taken these drugs than those 
who died. Importantly, we only considered use of drugs 
in the period between diagnosis and first infection so 
survival from first infection would not affect the propor-
tion of patients recorded as taking any drug.
Multiple organ involvement by infection was more 
common in deceased patients than in patients who 
survived (Pearson χ2=20.5, p=<0.001). Patients who 
died were more likely to have had positive anti-dsDNA 
compared with those who survived.
After multivariable analysis adjusted for age, previous 
hospitalisations due to SLE, previous infection and the 
presence of multiple organ involvement remained statis-
tically significant as factors differentiating patients who 
died from those who survived (β coefficient: −6.15, 95% CI 
−9.57 to −2.73; p<0.001; β coefficient: 3.55, 95% CI 0.47 to 
6.63; p=0.024 and β coefficient 3.51 95% CI 0.9 to 6.12; 
p=0.008).
Analysis of sLesIs values over time
Median (IQR) SLESIS at diagnosis of SLE in patients with 
infection was 4.27 (3.18) which was significantly higher 
than in the control (no infection) group (median 2.55, 
IQR 3.79 (z = −3.34; p=0.0008). Median (IQR) SLESIS 
Table 3 Comparison of patients who died during admission for severe infection and those who survived
Deceased patients n=26 
(26.5%)
Alive patients n=72 
(73.5%) P values
Mean age at diagnosis (SD) 33.8 (14.1) 31.2 (15.1) ns
Mean age at infection (SD) 42.88 (16.7) 40.88 (16.7) ns
Follow-up between diagnosis and first infection (years) 9.11 (7.04) 10.8 (10.3) ns
Ethnicity n, (%)
  Caucasian 16 (61.5) 31 (43.1) ns
  Hispanics NA 3 (4.2)
  Afro-Caribbean 8 (30.8) 20 (27.8)
  Asian 2 (7.7) 4 (5.6)
  Others NA 12 (16.7)
Gender (female), n (%) 25 (96) 65 (90) ns
Previous hospitalisations, n (%) 2 (8) 53 (74) <0.001
Previous severe infection before diagnosis of SLE, n (%) 9 (35) 7 (10) 0.003
Skin disease, n (%) 18 (69) 58 (81) ns
Renal disease, n (%) 10 (39) 32 (44) ns
Joint disease, n (%) 22 (85) 50 (69) ns
Neuropsychiatric disease, n (%) 4 (15) 9 (13) ns
Serositis, n (%) 7 (27) 12 (17) ns
Corticosteroids per day at any time), n (%) 20 (77) 69 (96) 0.02
Corticosteroids ≥10 mg/day at any time, n (%) 17 (65) 37 (51) ns
Hydroxychloroquine, n (%) 20 (77) 46 (64) ns
Rituximab, n (%) 1 (4) 25 (35) 0.002
Cyclophosphamide, n (%) 11 (42) 17 (24) ns
Azathioprine, n (%) 14 (54) 33 (46) ns
Mycophenolate, n (%) 10 (39) 26 (36) ns
Splenectomy, n (%) 0 3 (4) ns
Bacteraemia, n (%) 4 (15) 9 (13) ns
Multiple organ involvement, n (%) 12 (46) 5 (7) <0.001
Low complement, n (%) 11 (42) 46 (64) ns
Neutropenia, n (%) 5 (19) 28 (39) ns
Lymphopenia, n (%) 20 (77) 56 (78) ns
a-dsDNA, n (%) 20 (77) 47 (65) ns
a-dsDNA, Anti-double stranded DNAantibodies; SLE, systemic lupus erythematosus.
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just before the infection in the infection group was 6.64 
(4.18) which was statistically higher than the median 
SLESIS at diagnosis in those patients (z=−5.73, p=<0.001) 
and also higher than median SLESIS in the dura-
tion-matched control group at a comparable time point 
in their disease course (median 3.32, IQR 3.16, z=−6.99; 
p=<0.001). There were no statistically significant differ-
ences between the first and second SLESIS values (ie, 
diagnosis and comparable time point to infection) for 
the matched controls.
Figure 1 shows the ROC analysis for SLESIS at diag-
nosis. The AUC was 0.6332 (SD 0.04; 95% CI 0.56 to 0.70). 
We defined three possible cut-offs to distinguish patients 
with and without severe infection. We selected the cut-offs 
which had classified correctly the maximum percentage of 
the sample taking into account sensitivity and specificity. 
A cut-off for SLESIS at diagnosis ≥3.18 identified patients 
who would develop severe infection with sensitivity 77% 
and specificity 51%. For SLESIS ≥3.46, sensitivity was 66% 
and specificity 55%. For SLESIS ≥4.24, sensitivity was 64% 
and specificity 60%.
Figure 2 shows the ROC curve for SLESIS just prior to 
the infection. The AUC was 0.79 (SD 0.03 95% CI 0.73 
to 0.85), which was better than for SLESIS at diagnosis. 
We selected three cut-offs: ≥3.67 identified patients who 
would develop severe infection with sensitivity of 90% 
and specificity of 43%. Similar results were obtained 
using ≥3.79 as a cut-off (sensitivity of 88%, specificity of 
50%). For SLESIS ≥4.24, sensitivity was 86% and speci-
ficity 60%.
DIsCussIOn
In patients with SLE it has been reported that the preva-
lence of life-threatening infections appears to be highest 
within the first 5 years after disease onset.23 However, 
severe infection represents a threat throughout the course 
of the disease, especially when these patients become 
older and develop more comorbidities related to age. 
Given the potential mortality in patients with SLE due 
to such infections, it is pertinent to pursue new options 
that allow us to predict which groups of patients will have 
higher risk of developing major infections. Our aim was 
to develop a risk score (SLESIS) to aid in this purpose. 
This study fulfils the important task of testing the proper-
ties of this SLESIS score in a cohort independent of the 
RELESSER19 20 population in which it was developed. Our 
London cohort differs from the Spanish cohort in terms 
of ethnicity but SLESIS still exhibits a valid and statisti-
cally significant association with severe infection.
During the last few years, there have been several publi-
cations aiming to develop algorithms that could measure 
the risk of developing severe infections in patients with 
other autoimmune diseases. Crowson et al24 developed a 
score in order to detect severe infection promptly in a 
cohort of 410 patients with RA. The score was designed 
and validated to predict the 1-year risk of severe infec-
tion whereas SLESIS was elaborated to predict the risk of 
severe infection ever. Zink et al18 built a score based on the 
Rheumatoid Arthritis Observation of Biologic Therapy 
cohort in order to predict serious infection in patients 
on biologic treatment, with promising results. However, 
Figure 1 Receiver operator characteristics (ROC) curve analysis—Systemic Lupus  Erythematosus Severe Infection Score 
(SLESIS) at diagnosis.
 o
n
 28 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-028697 on 14 June 2019. Downloaded from 
7Tejera Segura B, et al. BMJ Open 2019;9:e028697. doi:10.1136/bmjopen-2018-028697
Open access
the authors suggested that their risk score was valid only 
in Caucasian populations in Western Europe. Beca et al25 
designed a risk calculator algorithm to differentiate flares 
from infections in patients with SLE with fever. The study 
encompassed 130 patients with SLE who presented with 
fever over a period of 13 years. ROC curve analysis in 
both papers showed that both scores were able to predict 
infection with an AUC between 0.8 and 0.9. Nonetheless, 
both studies validated the algorithms in similar cohorts 
in terms of ethnicity distribution compared with the orig-
inal cohorts. In contrast, we selected a validation cohort 
of patients in a different country, with a different range 
of ethnicities. In the Spanish cohort, 93% of patients 
were Caucasian and fewer than 1% African/Caribbean. 
In London, 68% were Caucasian and 28% African/
Caribbean, an ethnic group recognised as suffering more 
severe SLE.
Patients with previous severe infection were predis-
posed to developing major infection and were also 
more likely to die during admission for severe infection. 
Impaired immune system functions in a subgroup of 
patients with SLE may contribute to increase the infec-
tion risk in those patients. There are immunological and 
genetic disorders that predispose to the development of 
infections in patients with SLE. Furthermore, other clin-
ical and treatment factors might play a crucial role in the 
predisposition of patients with SLE to develop infection. 
For instance, the infection group were more likely than 
the controls to have had previous hospitalisations for 
SLE. These findings are comparable to other previous 
reports.2 26–28 In contrast, in the study of Ruiz-Irastorza et 
al, lung disease was the only clinical manifestation that 
was considered a predictor of major infection after the 
multivariate analysis.29
In carrying out this project, we noted the fact that a 
quarter of the patients recorded as suffering severe 
infections died during their admission for infection. To 
investigate this mortality further, we carried out univari-
able and multivariable analyses of factors that could 
potentially influence whether or not these patients died. 
Surprisingly, though previous hospitalisation due to SLE 
was a factor independently associated with increased risk 
of severe infection it was also associated with increased 
chance of surviving that severe infection, even after multi-
variable analysis. There is no obvious explanation for this 
apparent paradox. Perhaps the threshold for starting 
antibiotics was lower in such patients. We considered 
the possibility that deaths from severe infection had all 
occurred many years ago, during a period when more 
patients were treated with high-dose IS such as cyclophos-
phamide. However, this is not the case as 12 patients died 
between 2000 and 2012 while the other 14 died before 
the year 2000.
SLESIS was significantly higher just before the severe 
infection in comparison to the value at the diagnosis of 
SLE. This reinforces the idea that repeated measure-
ment of SLESIS may be a helpful clinical assessment tool. 
As lupus activity and treatment change over time, it is 
predictable that SLESIS would change over time, but it 
was important to investigate whether this makes SLESIS 
at diagnosis a poorer predictor of infection. Develop-
ment of chronic damage over time, as well as cumulative 
Figure 2 Receiver operator characteristics (ROC) curve analysis Systemic Lupus Erythematosus Severe Infection Score 
(SLESIS) before infection.
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use of corticosteroids and immunosuppressive drugs, 
could contribute to these changes in SLESIS related to 
increased infection risk. Some variables of SLESIS will 
never change over time, such as age at diagnosis, ethnicity 
and gender, whereas others, such as number of previous 
severe infections, Katz Index and current dose of corti-
costeroids, could change and may thus contribute to 
changes in SLESIS. One strategy could be to recalculate 
SLESIS annually and after every severe infection and 
hospitalisation. In this way, a prospective study could be 
carried out to calculate SLESIS multiple times during 
follow-up in order to assess its variation over time and see 
if its peak (vs lower values during follow-up) is really asso-
ciated with a higher probability of severe infection.
In line with other reports,30 31 we found that ever-use of 
corticosteroids ≥10 mg/day was associated with increased 
infection risk. In fact, more than 50% of patients of our 
cohort who suffered from severe infections had been 
treated with ≥10 mg/day of corticosteroids. Other immu-
nosuppressive treatments have been associated with high 
risk of infections although results have been controversial 
among the different cohorts.31 In our study, cyclophos-
phamide and azathioprine were associated with increased 
risk of severe infection in the univariate analysis but that 
significance was lost after the multivariable analysis.
There was a trend with HCQ which seemed to be the 
opposite to corticosteroids or IS, since fewer patients in 
the study group than the control group had ever been 
treated with HCQ. This finding is in agreement with 
previous reports29 32 although in our study, it did not 
reach statistical significance. Ruiz-Irastorza et al29 found 
that patients taking antimalarials were 16 times less likely 
to suffer a major infection. Similarly, Sisó et al32, found 
a lower frequency of infections among those previously 
treated with antimalarials in a retrospective study. Bultink 
et al, in a study designed to analyse the effect of the defi-
ciency of functional mannose-binding lectin, also found 
that treatment with HCQ was associated with fewer severe 
infections although the authors attributed this associa-
tion to the presumed lesser severity of patients with lupus 
who take HCQ.33
Overall, the AUCs in our study were not as high as for 
previous scores developed for RA.18 24 However, this is 
the first score that has been developed to predict severe 
infections in SLE and may represent the first step in 
developing tools to do this accurately. We acknowledge 
several limitations in our study. First is the retrospective 
design of the study. Second, the ethnicity item in SLESIS 
distinguishes only Latin-American ethnicity as a separate 
group, which was not helpful in the London population. 
A modified SLESIS including HR for other ethnic groups 
would be more widely applicable globally but could not 
have been derived from the RELESSER cohort (too ethni-
cally homogeneous) or the UCLH cohort (too small). 
Thirdly, the Katz Index used by RELESSER is a simple 
and helpful measure of disease severity (not just activity) 
but is not widely used in clinical practice. However, in 
the original RELESSER Study,17 from which SLESIS was 
derived, Systemic Lupus International Collaborating 
Clinics (SLICC)/ACR/Damage Index, Katz Index and 
SELENA-SLEDAI (Safety of Estrogen in Lupus National 
Assessmentstudy-Systemic Lupus Erythematosus Disease 
Activity Index) activity score were all measured and the 
Katz Index was the only one statistically associated with 
severe infection. Notwithstanding these limitations, we 
have shown that SLESIS at diagnosis was significantly 
higher in the group of patients who later suffered severe 
infections than in the control group of patients with SLE 
who did not suffer severe infection.
How might SLESIS be used in clinical practice? It is 
important to bear in mind that both sensitivity and speci-
ficity for severe infection were modest for SLESIS at diag-
nosis. For SLESIS just before the infection, sensitivity was 
high (90%) but specificity was low (54%). The low speci-
ficity means that SLESIS could not be used to decide on 
use of management measures with a high risk of adverse 
effects. We would suggest that patients with high SLESIS 
(>3.5) at any point could be followed up with a higher 
index of suspicion for infection and lower threshold for 
using antibiotics. Although this may be an obvious extrap-
olation of the data, it is not possible to conclude that the 
early use of antibiotics in patients with high SLESIS will 
impact on the outcomes, and therefore, this strategy 
cannot be suggested based solely on the results of our 
work. SLESIS at diagnosis, together with other factors, 
might also help in deciding which patients might benefit 
from vaccination against bacterial infections (eg, pneu-
mococcus) and considering a benefit-risk balance of 
corticosteroids (≥10 mg/day) and other IS.
In summary, despite the limitations, our study has 
demonstrated strong arguments to perform future 
prospective studies to assess if SLESIS, or an improved 
form of SLESIS, could be clinically useful in the early 
diagnosis and prevention of severe infections in patients 
with SLE.
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